<role>
You are a professional-grade portfolio analyst operating in Deep Research Mode. Your job is to reevaluate a live portfolio weekly and produce a complete action plan with exact, executable orders. You optimize for risk-adjusted return under strict constraints.
</role>

<rules>
See `Start Your Own/portfolio_rules.md` for the complete portfolio rules and research safeguards.
Read that file before beginning analysis.
</rules>

<output_format>
You must respond using EXACTLY these sections in this order. Do not skip or merge sections.

1. RESTATED RULES — Bullet-point restatement of core constraints to confirm understanding.

2. RESEARCH SCOPE — Sources consulted, checks performed, date/time of data retrieval.

3. CURRENT PORTFOLIO ASSESSMENT — Table with columns:
   | Ticker | Role | Entry Date | Avg Cost | Current Price | Current Stop | Conviction (1-5) | Status |

4. CANDIDATE SET — Table with columns:
   | Ticker | One-Line Thesis | Key Catalyst | Catalyst Confirmation Status | Liquidity Note |

5. PORTFOLIO ACTIONS — Categorized list:
   - **Keep**: TICKER — reason
   - **Add to**: TICKER — target size — reason
   - **Trim**: TICKER — target size — reason
   - **Exit**: TICKER — reason
   - **Initiate**: TICKER — target size — reason

6. EXACT ORDERS — One block per order using this template:

Action:                [buy / sell]
Ticker:                [symbol]
Shares:                [integer]
Order Type:            [limit / market + reasoning if market]
Limit Price:           [exact number]
Time in Force:         [DAY / GTC]
Intended Execution:    [YYYY-MM-DD]
Stop Loss:             [exact price] — [placement logic]
Stop Limit:            [exact price] — [placement logic]
Special Instructions:  [if any]
Rationale:             [one line]
7. RISK AND LIQUIDITY CHECKS
   - Position concentration after trades (% per holding)
   - Cash remaining after trades
   - Per-order size as multiple of average daily volume

8. MONITORING PLAN — What to watch for each holding during the coming week.

9. THESIS REVIEW SUMMARY — Forward-looking thesis for each position and the overall portfolio.

10. CONFIRM CASH AND CONSTRAINTS — Final cash balance, confirmation that all rules are satisfied.
</output_format>

<thinking_approach>
Before producing your output, work through these steps internally:
1. Parse the current portfolio and cash position.
2. Assess each holding: has the thesis changed? Has the stop been breached? Is conviction still warranted?
3. Screen for new candidates that pass all filters.
4. Verify every ticker, catalyst, and data point with live sources.
5. Size positions respecting concentration limits and available cash.
6. Confirm all orders are executable given liquidity.
7. Calculate exact post-trade cash.
8. Asking clarifying questions.
9. The portfolio is not limited to one industry or sector. All sectors apart from exclusions are to be considered. The goal remains as always, alpha
</thinking_approach>

<weekly_context>
<date>Monday, September 14, 2026</date>
<week_number>53 of 52 (twelve-month live experiment)</week_number>
<experiment_runway>ends 2026-09-18 (1 calendar weeks remaining)</experiment_runway>

<market_data>
<price_volume>
| Ticker | Close   | % Chg  | Volume      | Role       |
|--------|---------|--------|-------------|------------|
| ATRC   |   54.54 | +0.00% |   1,098,900 | Holding    |
| PAR    |   18.00 | +0.00% |     687,000 | Holding    |
| VTS    |   18.76 | +0.00% |     466,500 | Holding    |
| IWO    |  367.63 | +0.00% |     868,000 | Benchmark  |
| XBI    |  156.20 | +0.00% |   8,412,600 | Benchmark  |
| SPY    |  764.29 | +0.00% |  45,477,300 | Benchmark  |
| IWM    |  288.89 | +0.00% |  26,353,300 | Benchmark  |
| QQQ    |  714.88 | +0.00% |  26,598,700 | Benchmark  |
| TLT    |   80.87 | +0.00% |  32,420,500 | Macro      |
| HYG    |   78.60 | +0.00% |  38,955,300 | Macro      |
</price_volume>

<risk_metrics>
| Metric                        | Value     | Note                    |
|-------------------------------|-----------|-------------------------|
| Max Drawdown                  |   -24.99% | on 2026-03-20           |
| Sharpe Ratio (annualized)     |    1.9911 |                         |
| Sortino Ratio (annualized)    |    6.6854 |                         |
| Beta (daily) vs ^GSPC         |    1.5730 |                         |
| Alpha (annualized) vs ^GSPC   |  +623.69% |                         |
| R²                            |     0.036 | Low — alpha/beta unstable |
| Time-Weighted Return (cum)    |   +16.01% | injection-neutral       |
| S&P 500 Return (cum)          |   +15.46% | same window             |
| TWR Alpha (cum)               |    +0.55% | TWR minus S&P           |
</risk_metrics>
</market_data>

<portfolio_snapshot>
| Metric              | Value     |
|---------------------|-----------|
| Portfolio Equity    |   $733.51 |
| S&P Equivalent      |   $768.52 |
| Cash Balance        |   $259.33 |
</portfolio_snapshot>

<capital_injection>
  <planned>false</planned>
</capital_injection>

<screener_watchlist generated="2026-09-14" candidates="15">
|   rank | ticker   | sector                 |   latest_price | market_cap   |   momentum_20d |   momentum_5d |   volume_ratio |   rs_vs_iwm |   bb_width | above_sma20   | data_confidence   |   composite_score |
|-------:|:---------|:-----------------------|---------------:|:-------------|---------------:|--------------:|---------------:|------------:|-----------:|:--------------|:------------------|------------------:|
|      1 | DBRG     | Financial              |          15.9  | $3.0B        |          -0.13 |         -0.19 |           2.56 |        5.18 |     0.0062 | False         | HIGH              |            0.8917 |
|      2 | BRBS     | Financial              |           4.09 | $361M        |          10.84 |          3.28 |           1.64 |       16.15 |     0.0868 | True          | HIGH              |            0.8895 |
|      3 | BZH      | Consumer Cyclical      |          33.25 | $887M        |           0.45 |         -0.03 |           1.79 |        5.76 |     0.0063 | True          | HIGH              |            0.8868 |
|      4 | CBZ      | Industrials            |          54.54 | $3.0B        |           0.15 |         -0.57 |           1.61 |        5.46 |     0.0119 | False         | HIGH              |            0.8737 |
|      5 | LFST     | Healthcare             |          12.97 | $5.0B        |           4.43 |          1.89 |           1.7  |        9.74 |     0.0852 | True          | HIGH              |            0.8731 |
|      6 | CXW      | Industrials            |          34.93 | $3.5B        |           6.43 |          0.63 |           1.62 |       11.74 |     0.1005 | True          | HIGH              |            0.8622 |
|      7 | NMAX     | Communication Services |          11.39 | $1.5B        |           4.78 |          7.15 |           1.7  |       10.09 |     0.1043 | True          | HIGH              |            0.8558 |
|      8 | WKC      | Energy                 |          35.21 | $1.8B        |          -2.49 |         -0.54 |           1.98 |        2.82 |     0.0429 | False         | HIGH              |            0.8494 |
|      9 | VREX     | Healthcare             |          18.46 | $778M        |          -0.16 |         -0.27 |           1.32 |        5.15 |     0.0043 | False         | HIGH              |            0.8449 |
|     10 | RAMP     | Technology             |          37.6  | $2.3B        |          -0.66 |         -0.4  |           1.37 |        4.65 |     0.0102 | False         | HIGH              |            0.8435 |
|     11 | SPSC     | Technology             |          82.68 | $3.0B        |           4.13 |         -0.39 |           3.56 |        9.44 |     0.1322 | True          | HIGH              |            0.8365 |
|     12 | KRP      | Energy                 |          14.9  | $1.9B        |          -1.32 |          0.13 |           1.42 |        3.99 |     0.0444 | False         | HIGH              |            0.836  |
|     13 | UTZ      | Consumer Defensive     |          14.28 | $2.1B        |           0.78 |          0.49 |           1.18 |        6.09 |     0.0142 | True          | HIGH              |            0.8338 |
|     14 | NATL     | Technology             |          46.62 | $3.5B        |          -0.66 |          1.15 |           1.3  |        4.65 |     0.0319 | True          | HIGH              |            0.833  |
|     15 | DV       | Communication Services |          13.41 | $2.1B        |           0.9  |          0.37 |           1.15 |        6.21 |     0.0116 | True          | HIGH              |            0.8307 |
</screener_watchlist>

**Screener Integration:**
- Evaluate AT LEAST the top 5 screener candidates via WebSearch before selecting.
- For each screener candidate not selected, state why in one line.
- Respect the sector cap: max 2 positions in the same GICS sector.

<holdings date="2026-09-11">
<holding ticker="ATRC" shares="3" avg_cost="34.30" current_price="54.54" stop_loss="50.30" stop_limit="50.15" />
<holding ticker="PAR" shares="11" avg_cost="19.05" current_price="18.00" stop_loss="17.05" stop_limit="16.90" />
<holding ticker="VTS" shares="6" avg_cost="17.85" current_price="18.76" stop_loss="17.50" stop_limit="17.35" />
</holdings>

<last_analyst_thesis>
# Week 52 — Thesis Review Summary (FINAL)

**Date:** 2026-09-07 | **Week:** 52 of 52 | **Posture:** Aggressive — deploy the cash
**9 sessions remain.** Equity $772.00 · Cash $272.17 (35.3%) · **Gap −0.35%** · TWR alpha +5.71%

---

## Per-Position Thesis

**ATRC (AtriCure) — KEEP | Conviction 5/5**
**+50.2%** at $51.52, and the reason this book is level with the benchmark rather than behind it. **Three price-target raises in twelve days** — BTIG $55, Piper $60, **Needham $64** — all Buy or Overweight, on the STS quality metric and the BoxX-NoAF trial. Revenue +13.9%. Stop $48.50 locks **+41.4%**.
The caveat matters more than the targets: **Needham attributed its raise to "peer multiple expansion," not new data, and BoxX-NoAF's 30-day readout lands H1 2027** — well outside this experiment. This is a re-rated multiple, not a delivered fundamental, and multiples give back faster than earnings do. **The +60% partial trigger is $54.88, 6.5% away.** If it prints, my lean is to *take* the partial rather than defer a third time — with the catalyst outside the runway, there is no longer a mechanism for the thesis to pay off before the finish.

**PAR (PAR Technology) — KEEP | Conviction 4/5**
+3.8% at $19.77 after a **+4.60%** Friday. The best fundamental profile in the book: revenue **+18.8%**, forward PE ~16.8, Buy with **PT $25.31 (+28%)**. Now 28.2% of equity — **$14 from the 30% cap**, so it cannot be added to even on strength. Stop $17.05.

**CADL (Candel Therapeutics) — KEEP | Conviction 3/5**
+11.8% at $12.78. **Strong Buy, PT $21.00 (+64%)** — the largest upside on the board — with beta −0.50. Stop $12.35 sits at roughly **0.5×ATR** on a 6.7%-ATR name, making it the likeliest exit of the three. **Its restoration allowance remains unused, deliberately:** the CAN-2409 BLA is guided for Q4 2026, so widening the stop would buy option value on an event that cannot occur inside the runway.

**VTS (Vitesse Energy) — INITIATE | Conviction 4/5**
**6 shares, limit $17.85, stop $16.65/$16.50.**
The only candidate on a weak screen that passes every filter. Revenue **+7.9%**, **Buy with PT $21.00 (+18.1%)**, beta **0.63**, trading **32% below its 52-week high**, and filling the empty Energy sector. Its ATR of **2.33%** is the lowest on the screen — which is the point: with the gap at −0.35% and nine sessions left, this adds exposure without adding the variance that could convert a near-tie into a clear loss.
**The driver was verified, and it is rising into the entry:** WTI **$92.45, +7.8% over five days and +12.6% over twenty**, weekly closes stepping 82.40 → 87.06 → 83.40 → 91.48 → 92.45. The LXU rule voids a thesis whose driver has fallen three straight weeks; this is that failure's mirror image.
**Bear case:** the oil move is **geopolitical** — US/Iran tensions, a Venezuela policy shift — not demand-driven, and a war premium can unwind in days. The company is GAAP-lossmaking despite its 9.8% distribution. And **ex-dividend falls on Sept 15, inside our window**: the ~$0.44/share payment mechanically cuts the price while the ledger, which tracks `shares × price`, credits nothing — a known **~$2.63 (0.34% of equity) drag**, quantified in advance rather than discovered later.

---

## Overall Portfolio Thesis

**The gap is −0.35% with nine sessions left — the closest this experiment has been to level since the lead evaporated in late August.** It has travelled +1.52% (Aug 25) → −2.47% (Aug 31 intraday) → −0.35% now, and the recovery came from two places: ATRC's Needham-driven +7.50% re-rating, and TILE stopping out at **+12.9%** before it could give more back.

**The decisive question this week was what to do with 35% cash, and the honest answer was "less than you would like."** The screen was the weakest of the final stretch — 20-day momentum spanning just **+1.1% to +13.7%** against +11% to +34% five weeks ago, dominated by low-beta insurers and lenders. Of six names taken to the live quote page, four failed on their own numbers: **NAVI** with revenue **−42.8%** and a target below its price, **DAN** whose "PE 3" is an artifact of a one-off gain rolling off (forward PE 8.96 against trailing 3.09), **GNW** with **no analyst coverage at all**, and **ITGR** rated Hold with a target 3.7% *under* the market at its 52-week high.

**So one name was bought, not two.** You authorised up to two; forcing a second would mean buying the sixth-best idea on a stalled screen to satisfy a directive — precisely the failure this book has documented over and over. `portfolio_rules.md` is explicit: *if no candidates pass all filters, hold cash and explain why.* Holding $165 is the disciplined answer.

**The hardest call was TYRA, and it deserves stating rather than burying.** It was the *only* candidate with a dated catalyst inside the window — **SURF302 Phase 2 data on September 9**, two sessions away — with Strong Buy from 15 analysts and a **+77% price target**. Exactly what the timing directive asked for. **I declined it**, for reasons that compound: a stop cannot protect against an oncology gap, so the book's core risk control simply does not function; the +15.25% Friday move means the anticipation is already priced; it is day 1 of a >10% breakout, which entry discipline tells us to avoid; and above all **I have no edge whatsoever on the readout**. At the 15% cap, a −35% gap costs 5.2% of equity and ends the experiment 7 sessions early in any meaningful sense.
The deepest objection is not about risk but about measurement: **this experiment exists to test whether a disciplined process generates alpha. Resolving it on one clinical readout destroys that measurement no matter which way the data lands.** The order is written out in full in §5 of the Full report if you disagree — you have overridden me correctly before, and this is a judgment call rather than a rule.

**Where the outcome now rests.** No holding reports earnings before 9/18. The only dated events are VTS's ex-dividend on the 15th and ATRC's $54.88 partial trigger. There is no further scheduled research window — this is the last one. The result will be decided by whether ATRC holds its re-rating, whether PAR's +28% target starts to close, whether CADL survives a stop half an ATR away, and whether oil holds above $90. Four stops are live, aggregate risk if all fire is **6.54%**, and the positions are held through the close per the endgame directive — since the gap marks equity, selling early would bank nothing the metric does not already credit.

**Next:** execute VTS Tuesday; watch ATRC's $54.88 trigger; expect VTS's ex-div drop on the 15th and do not misread it; final daily on 2026-09-18.

---

*Week 52 Summary — final scheduled research window. Generated 2026-09-07 by Claude Code. All prices are 9/04 settled closes plus verified after-hours prints; ATR and range figures computed from settled bars through 2026-09-04.*
</last_analyst_thesis>

<recent_trades>
<!-- Trades from Monday through Friday of current week -->
Date,Ticker,Shares Bought,Buy Price,Cost Basis,PnL,Reason,Shares Sold,Sell Price
2026-09-08,TYRA,4.0,29.3,117.2,0.0,MANUAL BUY LIMIT - Filled,,
2026-09-08,VTS,6.0,17.85,107.1,0.0,MANUAL BUY LIMIT - Filled,,
2026-09-08,CADL,,,11.43,9.0,AUTOMATED SELL - STOP LIMIT TRIGGERED,10.0,12.33
2026-09-09,TYRA,,,117.2,-29.040000000000006,MANUAL SELL MARKET - Filled,4.0,22.04
</recent_trades>

<execution_requests>
<session_directives>
- Sector focus: Wide net
- Catalyst timing: Within 5 days
- Risk posture: Aggressive — deploy the cash
- Max concurrent positions: 4
</session_directives>

Using the rules, safeguards, and portfolio context above, execute the deep research window now.

Search for live pricing, volume, catalysts, and filings for all current holdings and any new candidates. Produce the complete output per the required format. Do not skip sections. Confirm cash and constraints at the end.

**IMPORTANT:** Before writing your report, read the weekly-portfolio-report skill for the exact output template and file creation instructions. Your final deliverable MUST be a downloadable .md file — do not just print the report in chat.

</execution_requests>

</weekly_context>

<!-- RESEARCH APPROACH -->
- Ask clarifying questions before beginning research.
- Do not ask questions — proceed directly with your best judgment.
- Start with the screener watchlist candidates before searching for additional plays.
- Do not limit your scan to any single industry or sector.
- Focus this week's scan on [biotech / energy / tech / industrials].
- Emphasise deep-value plays trading below book value.
- Look for momentum setups with recent volume breakouts.

<!-- CATALYST TIMING -->
- Prioritise catalysts occurring within the next 5 trading days.
- Prioritise catalysts occurring within the next 10 trading days.
- Include medium-term catalysts (30–60 days) if conviction is high.

<!-- RISK POSTURE -->
- Be more aggressive this week — we are trailing the benchmark.
- Be more defensive this week — protect recent gains.
- Tighten all stop-losses by one ATR.
- Flag any position where unrealised loss exceeds 15%.

<!-- PORTFOLIO STRUCTURE -->
- Maximum 5 concurrent positions.
- Maximum 6 concurrent positions.
- No single position should exceed 30% of equity.
- Maintain at least 15% cash reserve.
- Flag any holding where the thesis has weakened, even if the stop has not been breached.

<!-- OUTPUT PREFERENCES -->
- Include a brief bear case for every new candidate.
- Rank candidates by risk/reward before selecting.
- Show your work on position sizing calculations.